Top

Published in:

01-03-2016 | Original Article

Expression analysis of four long noncoding RNAs in breast cancer

Authors: Mostafa Iranpour, Mohammad Soudyab, Lobat Geranpayeh, Reza Mirfakhraie, Eznollah Azargashb, Abolfazl Movafagh, Soudeh Ghafouri-Fard

Published in: Tumor Biology | Issue 3/2016

Abstract

Breast cancer is a molecularly heterogeneous disease which necessitates a search for markers to provide a more specific classification of this disorder. Long noncoding RNAs as the important subset of noncoding transcripts have been shown to be involved in tumorigenic processes. So, they may be used as markers for early detection of cancer and evaluation of cancer prognosis. In addition, they can be applied as therapeutic targets. In this study, we analyzed expression of four long noncoding RNAs (lncRNAs) namely SOX2OT, PTPRG-AS1, ANRASSF1, and ANRIL in 38 breast cancer tissues and their adjacent noncancerous tissues (ANCTs). ANRASSF1 expression was not detected in any noncancerous tissue. All lncRNAs showed significant overexpression in tumor tissues compared with ANCTs. No association was found between gene expressions and individual clinical data such as tumor stage, grade, size and hormone receptor status except for ANRASSF1 expression and Her2/neu status. In addition, ANRASSF1 and ANRIL expressions were significantly higher in triple negative samples. This study suggests a putative role for these lncRNAs in breast cancer and implies that they can be used as potential cancer biomarkers.

Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412.CrossRef

Mobasheri MB, Shirkoohi R, Zendehdel K, Jahanzad I, Talebi S, Afsharpad M, et al. Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines. Tumour Biol. 2015. doi:10.1007/s13277-015-3546-4.PubMed

Meng J, Li P, Zhang Q, Yang Z, Fu S. A four-long non-coding RNA signature in predicting breast cancer survival. J Exp Clin Cancer Res. 2014;33(1):84. doi:10.1186/s13046-014-0084-7.CrossRefPubMedPubMedCentral

Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis. 2014;5:e1008. doi:10.1038/cddis.2013.541.CrossRefPubMedPubMedCentral

Zhao W, Luo J, Jiao S. Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep. 2014;4:6591. doi:10.1038/srep06591.CrossRefPubMedPubMedCentral

Shahryari A, Jazi MS, Samaei NM, Mowla SJ. Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet. 2015;6:196. doi:10.3389/fgene.2015.00196.CrossRefPubMedPubMedCentral

Askarian-Amiri ME, Seyfoddin V, Smart CE, Wang J, Kim JE, Hansji H, et al. Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer. PLoS One. 2014;9(7):e102140. doi:10.1371/journal.pone.0102140.CrossRefPubMedPubMedCentral

Beckedorff FC, Ayupe AC, Crocci-Souza R, Amaral MS, Nakaya HI, Soltys DT, et al. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 2013;9(8):e1003705. doi:10.1371/journal.pgen.1003705.CrossRefPubMedPubMedCentral

Congrains A, Kamide K, Ohishi M, Rakugi H. ANRIL: molecular mechanisms and implications in human health. Int J Mol Sci. 2013;14(1):1278–92. doi:10.3390/ijms14011278.CrossRefPubMedPubMedCentral

10.

Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, et al. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal. 2013;25(5):1086–95. doi:10.1016/j.cellsig.2013.02.006.CrossRefPubMedPubMedCentral

11.

Seifi-Alan M, Shamsi R, Ghafouri-Fard S, Mirfakhraie R, Zare-Abdollahi D, Movafagh A, et al. Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev. 2014;14(11):6625–9.CrossRefPubMed

12.

Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, Ghafouri-Fard S, Savad S, et al. Expression of testis specific genes TSGA10, TEX101 and ODF3 in breast cancer. Iran Red Crescent Med J. 2012;14(11):722–6. doi:10.5812/ircmj.3611.CrossRefPubMedPubMedCentral

13.

Kazemi-Oula G, Ghafouri-Fard S, Mobasheri MB, Geranpayeh L, Mohammad Hossein Modarressi. Upregulation of RHOXF2 and odf4 expression in breast cancer tissues. Cell J (Yakhteh). 2015.

14.

Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 2006;8(5):R58. doi:10.1186/bcr1608.CrossRefPubMedPubMedCentral

15.

Casbas-Hernandez P, Sun X, Roman-Perez E, D’Arcy M, Sandhu R, Hishida A, et al. Tumor intrinsic subtype is reflected in cancer-adjacent tissue. Cancer Epidemiol Biomarkers Prev. 2015;24(2):406–14. doi:10.1158/1055-9965.epi-14-0934.CrossRefPubMed

16.

Shahryari A, Rafiee MR, Fouani Y, Oliae NA, Samaei NM, Shafiee M, et al. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma. Stem Cells. 2014;32(1):126–34. doi:10.1002/stem.1542.CrossRefPubMed

17.

Pasmant E, Sabbagh A, Vidaud M, Bieche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011;25(2):444–8. doi:10.1096/fj.10-172452.CrossRefPubMed

18.

Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009;33(5):759–67. doi:10.1097/PAS.0b013e31819437f9.CrossRefPubMedPubMedCentral

Title: Expression analysis of four long noncoding RNAs in breast cancer
Authors: Mostafa Iranpour
Mohammad Soudyab
Lobat Geranpayeh
Reza Mirfakhraie
Eznollah Azargashb
Abolfazl Movafagh
Soudeh Ghafouri-Fard
Publication date: 01-03-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4135-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer

3-Bromopyruvate inhibits cell proliferation and induces apoptosis in CD133+ population in human glioma

Resveratrol inhibits oral squamous cell carcinoma through induction of apoptosis and G2/M phase cell cycle arrest

Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer

Lin28: an emerging important oncogene connecting several aspects of cancer

The clinical significance of vascular endothelial growth factor in malignant ascites

Keynote webinar | Spotlight on antibody–drug conjugates in cancer